Clinical Case: 68-Year-Old Diabetic with Chest Pain — NSTEMI Workup and Management

Version 1.0 — Published March 2026

The case

A 68-year-old retired schoolteacher presents to the emergency department with central chest discomfort that started 3 hours earlier while watching television. He describes the pain as a heavy pressure ("like a weight on the chest"), radiating to the left arm and jaw, accompanied by mild dyspnea and diaphoresis. The pain has partially eased from its peak intensity but has not fully resolved.

He has a 12-year history of type 2 diabetes mellitus (on metformin 1 g twice daily and glimepiride 2 mg daily), hypertension for 15 years (on amlodipine 5 mg and telmisartan 40 mg daily), and dyslipidemia (on atorvastatin 10 mg at night — a moderate-intensity dose). He has never smoked. He has no prior history of coronary artery disease or stroke. Family history is significant for myocardial infarction in his father at age 62.

On arrival, his vitals are: pulse 96 bpm regular, BP 150/90 mmHg (both arms), respiratory rate 20/min, SpO2 95 percent on room air, temperature 98.4 F. He appears anxious and mildly diaphoretic but is in no acute distress.

History and examination

Acute coronary syndrome (ACS) is the immediate clinical anchor in any elderly diabetic with anginal-pattern chest pain. In India, ischemic heart disease contributes 28 percent of all deaths (ICMR Global Burden of Disease, 2022), and diabetes accelerates atherosclerosis by 2-4 fold. Diabetic autonomic neuropathy may blunt the severity of typical anginal pain — the "silent MI" pattern described by the Framingham study in 20-25 percent of diabetic infarcts. This patient's symptoms are clearly anginal, but the masking effect means a lower threshold for investigation is appropriate.

Cardiovascular examination:

• Pulse: 96 bpm, regular, normal volume
• JVP: not elevated
• Apex beat: in the 5th intercostal space, midclavicular line (not displaced)
• Heart sounds: S1 and S2 normal, no S3 or S4, no murmur, no pericardial rub
• No pedal edema

Respiratory examination:

• Symmetric chest expansion
• Vesicular breath sounds bilaterally, no crackles or wheeze
• No signs of pulmonary edema

Systemic:

• No features of heart failure (no raised JVP, no basal crackles, no S3 gallop)
• Peripheral pulses all palpable and symmetric (helps rule out aortic dissection in the differential)
• No radio-radial or radio-femoral delay
• Neurological examination normal (no focal deficit to suggest stroke)

Bedside 12-lead ECG (taken within 10 minutes of arrival):

• Sinus rhythm at 96 bpm
• Normal axis, normal PR and QRS intervals
• T-wave inversions in V3, V4, V5, V6 (anterolateral leads)
• No ST-segment elevation in any lead
• No pathological Q waves
• No evidence of left ventricular hypertrophy or bundle branch block

Differential diagnosis

Acute NSTEMI is the leading diagnosis, but the differential for acute chest pain in an elderly diabetic is broad. The top 6 conditions to rule in or rule out:

The T-wave inversions localized to V3-V6 (anterolateral leads) plus elevated troponin and typical anginal features clinch the diagnosis: acute NSTEMI involving the anterolateral territory, likely from a subtotally occluded left anterior descending (LAD) or first diagonal branch.

Investigations

Cardiac troponin is the single most important investigation in suspected ACS. This patient's results:

• Troponin I at 0 hours: 0.15 ng/mL (upper limit of normal 0.05 ng/mL — 3x ULN)
• Troponin I at 3 hours: 0.42 ng/mL (rising pattern — confirms acute myocardial injury)
• CK-MB: 12 ng/mL (elevated; normal below 5)
• NT-proBNP: 450 pg/mL (mildly elevated, reflecting ventricular wall stress)

The rising troponin pattern with clinical anginal features and ischemic ECG changes satisfies the Fourth Universal Definition of Myocardial Infarction (2018) — specifically Type 1 MI (atherothrombotic, plaque rupture).

Additional investigations:

• CBC: Hb 13.2 g/dL, WBC 9,800/mm3, platelets 245,000/mm3 (all within normal limits)
• Electrolytes and renal function: Na 138 mEq/L, K 4.2 mEq/L, creatinine 1.1 mg/dL (eGFR 68 mL/min)
• Random blood glucose: 214 mg/dL (reflects stress hyperglycemia plus background diabetes)
• HbA1c: 8.1 percent (poorly controlled diabetes — a modifiable risk factor for aggressive secondary prevention)
• Lipid profile: Total cholesterol 220, LDL 152, HDL 34, triglycerides 180 mg/dL — inadequate control on moderate-intensity statin
• Chest X-ray: Normal cardiac silhouette, clear lung fields, no features of pulmonary edema or widened mediastinum
• Bedside echocardiogram: Mild regional wall motion abnormality in the anterolateral wall with preserved overall LV function (LVEF approximately 50 percent). No significant valvular disease. No pericardial effusion.

Diagnosis

Acute non-ST elevation myocardial infarction (NSTEMI) — anterolateral territory in a 68-year-old diabetic hypertensive male. Estimated vessel: left anterior descending artery (LAD) or first diagonal branch with subtotal occlusion.

Risk stratification

Two scores guide the invasive-vs-conservative decision and NEET PG tests both.

TIMI risk score for NSTEMI/UA (each criterion = 1 point; score range 0-7):

TIMI score: 5 (high risk; 26 percent 14-day risk of death, MI, or urgent revascularization)

GRACE risk score uses age, heart rate, systolic BP, creatinine, Killip class, cardiac arrest at admission, ST-segment deviation, and elevated cardiac enzymes. For this patient, the estimated GRACE score is approximately 145-155 — high risk (score above 140 indicates mortality above 3 percent at 6 months).

Both scores place him firmly in the high-risk group requiring an early invasive strategy.

Management

Management of NSTEMI follows a stepwise protocol. The order matters — NEET PG tests sequence and timing, not just drug lists.

Step 1: Immediate anti-ischemic and antiplatelet therapy (first 30 minutes)

1. Aspirin 300 mg chewed and swallowed, then 75-100 mg daily maintenance. Aspirin reduces death and MI by 50 percent in ACS (ISIS-2, Lancet 1988).
2. P2Y12 inhibitor loading — ticagrelor 180 mg orally (preferred in most NSTEMI patients per PLATO trial) or clopidogrel 600 mg (acceptable alternative, especially if oral anticoagulation is already present or high bleeding risk). Prasugrel 60 mg is reserved for patients proceeding directly to PCI without stroke history.
3. Anticoagulation — fondaparinux 2.5 mg subcutaneously daily (preferred; OASIS-5 showed reduced bleeding vs enoxaparin) OR enoxaparin 1 mg/kg subcutaneously twice daily if early PCI is planned.
4. Sublingual nitroglycerin 0.4 mg every 5 minutes up to 3 doses for ongoing chest pain. Start IV nitroglycerin infusion if pain persists or if hypertension/heart failure. Contraindications: SBP below 90, recent sildenafil use, RV infarction.
5. Oral beta-blocker within 24 hours — metoprolol tartrate 25-50 mg every 6-12 hours. Avoid IV beta-blockers in the acute setting (COMMIT trial, Lancet 2005, showed increased cardiogenic shock).
6. High-intensity statin — atorvastatin 80 mg at night regardless of baseline LDL. The PROVE-IT TIMI 22 trial (NEJM, 2004) demonstrated 16 percent event reduction vs moderate-intensity.
7. Oxygen only if SpO2 below 90 percent — routine oxygen is no longer recommended (AVOID trial, Circulation 2015).

Step 2: Supportive measures

• Continuous cardiac monitoring for 24-48 hours to detect arrhythmias (ventricular tachycardia in 2-5 percent of NSTEMI).
• Pain reassessment every 15-30 minutes. Persistent pain despite nitrates is a very high-risk feature requiring urgent angiography.
• Glycemic control — target glucose 140-180 mg/dL during hospitalization. Insulin infusion if glucose above 180 consistently. Avoid tight control (below 110) — the NICE-SUGAR trial (NEJM 2009) showed hypoglycemia increases mortality.
• Bed rest for first 24 hours, then progressive mobilization.

Step 3: Coronary angiography and revascularization

Based on this patient's high-risk features (TIMI 5, GRACE above 140, elevated troponin, dynamic ECG changes), early invasive strategy — coronary angiography within 24 hours — is indicated per 2023 ESC and 2021 ACC/AHA ACS guidelines.

Revascularization approach is determined at angiography: PCI with drug-eluting stent for single or two-vessel disease; CABG preferred for left main disease, triple-vessel disease with diabetes, or complex coronary anatomy (SYNTAX score above 32).

For comprehensive coverage of ACS management, see our myocardial infarction management guide and strengthen your medicine subject coverage with targeted practice.

Step 4: Secondary prevention (started before discharge)

All NSTEMI patients require the following long-term therapy unless contraindicated:

Additional measures: smoking cessation (though not applicable here), structured cardiac rehabilitation (reduces all-cause mortality by 13 percent — Cochrane review 2021), glycemic optimization targeting HbA1c below 7 percent, blood pressure target below 130/80 for diabetics, influenza vaccination annually, and lifestyle modification (Mediterranean diet, 150 minutes moderate-intensity exercise weekly).

How NEET PG tests NSTEMI

NSTEMI appears in 1-2 NEET PG questions per paper, tested through four dominant patterns:

Pattern 1 — The troponin interpretation question: A patient with chest pain, normal initial ECG or T-wave inversions, and serial troponin showing a rise. The answer is NSTEMI. The trap: choosing unstable angina (normal troponin definition) or STEMI (requires ST elevation). High-sensitivity troponin thresholds are 14 ng/L (women) and 22 ng/L (men); serial sampling at 0h and 1-3h detects rising/falling pattern.

Pattern 2 — The risk stratification question: Given clinical features, calculate TIMI or GRACE score. A TIMI score of 3 or higher or GRACE above 140 indicates invasive strategy within 24 hours. Memorize the 7 TIMI criteria — they are testable directly.

Pattern 3 — The timing-of-angiography question: Which patient needs angiography immediately vs within 24 hours vs within 72 hours? Hemodynamic instability or refractory angina = immediate. High-risk features (GRACE above 140, troponin rise, dynamic ECG) = within 24 hours. Intermediate-risk = within 72 hours.

Pattern 4 — The management sequence question: What is the first-line antiplatelet? (Aspirin.) Which P2Y12 inhibitor is preferred in most NSTEMI? (Ticagrelor per PLATO.) Which anticoagulant has the best bleeding profile? (Fondaparinux per OASIS-5.) When do you start a high-intensity statin? (Before discharge, regardless of LDL.)

High-yield one-liners for last-day revision:

• NSTEMI = elevated troponin + no ST elevation (ST depression or T-wave inversions possible)
• Unstable angina = ischemic symptoms + normal troponin (by definition)
• Very high-risk NSTEMI features (hemodynamic instability, refractory angina) → angiography within 2 hours
• TIMI score 0-2 is low risk; 3-4 intermediate; 5-7 high
• Ticagrelor preferred over clopidogrel in most NSTEMI (PLATO, 2009)
• Fondaparinux is the preferred anticoagulant for conservative strategy or delayed invasive (OASIS-5)
• Oxygen in ACS only if SpO2 below 90 percent (AVOID trial, 2015)
• LDL target after ACS is below 55 mg/dL per 2023 ESC guidelines

Frequently asked questions

What distinguishes NSTEMI from unstable angina?

NSTEMI and unstable angina both present with ischemic chest pain and no ST elevation on ECG. The single distinguishing feature is cardiac troponin — elevated in NSTEMI, normal in unstable angina. ECG findings (T-wave inversions, ST depression) can be identical in both. High-sensitivity troponin assays detect myocardial injury at thresholds of 14 ng/L for women and 22 ng/L for men. A rising or falling troponin pattern on serial sampling (0h and 1-3h) is diagnostic of NSTEMI per the Fourth Universal Definition of Myocardial Infarction (2018).

When is immediate coronary angiography indicated in NSTEMI?

Immediate (within 2 hours) angiography is indicated for very high-risk NSTEMI — hemodynamic instability, cardiogenic shock, refractory angina despite medical therapy, life-threatening arrhythmias, or mechanical complications. Early (within 24 hours) angiography is indicated for high-risk patients with GRACE score above 140, dynamic ST changes, or elevated troponin. Delayed (within 72 hours) angiography suits intermediate-risk patients. Conservative strategy with non-invasive testing is reserved for low-risk patients (TIMI 0-2, GRACE below 109) without recurrent symptoms.

What is the TIMI risk score and how is it used in NSTEMI?

The TIMI risk score for NSTEMI/UA uses 7 variables, each scoring 1 point: age 65 or above, 3 or more CAD risk factors, known CAD (50 percent stenosis), aspirin use in the past 7 days, severe angina (2 or more episodes in 24 hours), ST deviation of 0.5 mm or more, and positive cardiac markers. Score 0-2 is low risk (less than 8 percent 14-day event rate), 3-4 intermediate (13-20 percent), 5-7 high (26-41 percent). A score of 3 or higher favors invasive strategy.

What is the loading dose of DAPT in NSTEMI?

Dual antiplatelet therapy (DAPT) in NSTEMI uses aspirin plus a P2Y12 inhibitor. Aspirin loading dose is 150-325 mg chewed. P2Y12 loading options are clopidogrel 600 mg, ticagrelor 180 mg, or prasugrel 60 mg (prasugrel is reserved for patients going to PCI; avoid if prior stroke or weight below 60 kg). Ticagrelor is preferred over clopidogrel in most NSTEMI patients per the PLATO trial (NEJM, 2009) which showed 16 percent relative risk reduction in cardiovascular death. Maintenance doses are aspirin 75-100 mg daily, clopidogrel 75 mg daily, ticagrelor 90 mg twice daily, prasugrel 10 mg daily.

Which anticoagulant is preferred in NSTEMI?

Fondaparinux 2.5 mg subcutaneously daily is the preferred anticoagulant for most NSTEMI patients undergoing conservative management or delayed invasive strategy — it has the best safety profile with reduced major bleeding compared to enoxaparin (OASIS-5 trial, NEJM 2006). Enoxaparin 1 mg/kg twice daily is preferred if PCI is planned within 24 hours. Unfractionated heparin is used during PCI itself (70-100 U/kg bolus). Bivalirudin is an alternative in patients at high bleeding risk. Anticoagulation is continued until PCI or for the duration of hospital stay.

What is the role of beta-blockers in NSTEMI?

Oral beta-blockers should be started within the first 24 hours in all NSTEMI patients without contraindications. Metoprolol tartrate 25-50 mg every 6-12 hours or carvedilol 6.25 mg twice daily are first-line options. Beta-blockers reduce myocardial oxygen demand, limit infarct size, and prevent arrhythmias. Contraindications include cardiogenic shock, hypotension (SBP below 90), bradycardia (HR below 60), second or third-degree AV block, decompensated heart failure, and severe asthma. Intravenous beta-blockers are avoided in the acute setting after the COMMIT trial (Lancet, 2005) showed increased cardiogenic shock with IV metoprolol.

What are the criteria for statin therapy in NSTEMI?

All NSTEMI patients should receive high-intensity statin therapy — atorvastatin 40-80 mg daily or rosuvastatin 20-40 mg daily — regardless of baseline LDL. The PROVE-IT TIMI 22 trial (NEJM, 2004) showed high-intensity statin reduced cardiovascular events by 16 percent compared to moderate-intensity. The LDL target after ACS is below 55 mg/dL per 2023 ESC guidelines. If LDL remains above target despite maximally tolerated statin, add ezetimibe 10 mg daily, then consider PCSK9 inhibitors (evolocumab, alirocumab) for persistently elevated LDL.

How is NSTEMI tested in NEET PG?

NBE tests NSTEMI through four patterns: troponin interpretation (distinguishing NSTEMI from unstable angina), TIMI or GRACE risk stratification questions (calculate score and decide invasive vs conservative), initial management sequence (order of aspirin, P2Y12, anticoagulation, beta-blocker, statin), and timing of angiography based on risk tier. Expect 1-2 NSTEMI questions per NEET PG paper within the medicine section, often as clinical vignettes with ECG and lab data requiring integrated decision-making.

Sources and references

1. Byrne RA et al., "2023 ESC Guidelines for the management of acute coronary syndromes," European Heart Journal, 2023 — definitive guideline for NSTEMI diagnosis, risk stratification, and invasive strategy timing.
2. Harrison's Principles of Internal Medicine, 21st Edition (Loscalzo et al., 2022) — comprehensive chapter on unstable angina/NSTEMI pathophysiology and management.
3. Wallentin L et al., "Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes (PLATO trial)," New England Journal of Medicine, 2009 — landmark trial establishing ticagrelor superiority in ACS.

Strengthen your cardiology clinical reasoning by working through practice vignettes. Review the full myocardial infarction management guide, build your medicine subject coverage, and drill targeted ACS questions on the NEETPGAI practice platform. Ready for unlimited AI-powered MCQs with detailed explanations? Explore NEETPGAI Pro.

For personalized study guidance on cardiology and other high-yield topics, try the AI Tutor — it adapts to your weak areas and explains concepts the way a senior resident would.

---

Written by: NEETPGAI Editorial Team Reviewed by: Pending SME Review Last reviewed: March 2026

This article is reviewed by qualified medical professionals for clinical accuracy and exam relevance. For corrections or updates, contact the editorial team.